anti-PD-1 therapy
1 product
2 abstracts
Abstract
A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study).Org: The Second Affiliated Hospital of Soochow University, Department of Radiotherapy & Oncology,
Abstract
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.Org: Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China,
Product
Anti-PD-1 Therapy